David K Simon

List of Publications by Year
in descending order

74 papers	7,022 citations	87888 38 h-index	85541 71 g-index
76 all docs	76 docs citations	76 times ranked	10671 citing authors

#	Article	IF	Citations
1	Associations between exercise classes and self-reported exercise by people with Parkinsonâ€™s disease at Parkinsonâ€™s foundation centers of excellence. Clinical Parkinsonism & Related Disorders, 2022, 6, 100137.	0.9	0
2	Differences in the Presentation and Progression of Parkinson's Disease by Sex. Movement Disorders, 2021, 36, 106-117.	3.9	54
3	The Relationship Between Olfactory Dysfunction and Constipation in Early Parkinson's Disease. Movement Disorders, 2021, 36, 781-782.	3.9	3
4	Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease. JAMA Neurology, 2021, 78, 312.	9.0	83
5	A New Approach to the Development of <scp>Diseaseâ€Modifying</scp> Therapies for <scp>PD</scp>. Movement Disorders, 2021, 36, 1281-1281.	3.9	0
6	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. JAMA - Journal of the American Medical Association, 2021, 326, 926.	7.4	80
7	Acute readmission following deep brain stimulation surgery for Parkinson's disease: A nationwide analysis. Parkinsonism and Related Disorders, 2020, 70, 96-102.	2.2	6
8	Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clinics in Geriatric Medicine, 2020, 36, 1-12.	2.6	487
9	VPS35 and the mitochondria: Connecting the dots in Parkinson's disease pathophysiology. Neurobiology of Disease, 2020, 145, 105056.	4.4	19
10	Boxing Exercises as Therapy for Parkinson Disease. Topics in Geriatric Rehabilitation, 2020, 36, 160-165.	0.4	4
11	Efficacy of Deep Brain Stimulation in a Patient with Genetically Confirmed Chorea-Acanthocytosis. Case Reports in Neurology, 2019, 11, 199-204.	0.7	5
12	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. Movement Disorders, 2019, 34, 1839-1850.	3.9	122
13	Altered muscle electrical tissue properties in a mouse model of premature aging. Muscle and Nerve, 2019, 60, 801-810.	2.2	11
14	Genetic risk of Parkinson disease and progression:. Neurology: Genetics, 2019, 5, e348.	1.9	109
15	Transportation innovation to aid Parkinson disease trial recruitment. Contemporary Clinical Trials Communications, 2019, 16, 100449.	1.1	6
16	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology, 2019, 92, 329-337.	1.1	194
17	Inverse Probability Weighted Cox Regression for Doubly Truncated Data. Biometrics, 2018, 74, 481-487.	1.4	21
18	Biomarkerâ€driven phenotyping in Parkinson's disease: A translational missing link in diseaseâ€modifying clinical trials. Movement Disorders, 2017, 32, 319-324.	3.9	145

#	Article	IF	Citations
19	Caffeine, creatine, GRIN2A and Parkinson's disease progression. Journal of the Neurological Sciences, 2017, 375, 355-359.	0.6	23
20	Autonomic and electrocardiographic findings in Parkinson's disease. Autonomic Neuroscience: Basic and Clinical, 2017, 205, 93-98.	2.8	19
21	Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. Journal of the Neurological Sciences, 2017, 377, 137-143.	0.6	27
22	Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores. Neurology, 2017, 89, 1789-1794.	1.1	24
23	Mitochondrial DNA mutations in Parkinson's disease brain. Acta Neuropathologica Communications, 2017, 5, 33.	5.2	7
24	Clinical Impact of ¹²³I-Ioflupane SPECT (DaTscan) in a Movement Disorder Center. Neurodegenerative Diseases, 2017, 17, 38-43.	1.4	13
25	Head injury at early ages is associated with risk of Parkinson's disease. Parkinsonism and Related Disorders, 2016, 23, 57-61.	2.2	50
26	Complicated spontaneous intracranial hypotension treated with intrathecal saline infusion. Practical Neurology, 2016, 16, 146-149.	1.1	12
27	Peripheral Biomarkers of Parkinsonâ€™s Disease Progression and Pioglitazone Effects. Journal of Parkinson's Disease, 2015, 5, 731-736.	2.8	25
28	Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease. JAMA - Journal of the American Medical Association, 2015, 313, 584.	7.4	192
29	Caffeine and Progression of Parkinson Disease. Clinical Neuropharmacology, 2015, 38, 163-169.	0.7	25
30	Metabolomic analysis of exercise effects in the POLG mitochondrial DNA mutator mouse brain. Neurobiology of Aging, 2015, 36, 2972-2983.	3.1	34
31	Rapamycin drives selection against a pathogenic heteroplasmic mitochondrial DNA mutation. Human Molecular Genetics, 2014, 23, 637-647.	2.9	79
32	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543.	9.0	312
33	Computationally simple estimation and improved efficiency for special cases of double truncation. Lifetime Data Analysis, 2014, 20, 335-354.	0.9	12
34	Somatic mitochondrial DNA mutations do not increase neuronal vulnerability to MPTP in young POLG mutator mice. Neurotoxicology and Teratology, 2014, 46, 62-67.	2.4	14
35	No Sex Differences in Use of Dopaminergic Medication in Early Parkinson Disease in the US and Canada - Baseline Findings of a Multicenter Trial. PLoS ONE, 2014, 9, e112287.	2.5	12
36	The inverse association of cancer and Alzheimer's: a bioenergetic mechanism. Journal of the Royal Society Interface, 2013, 10, 20130006.	3.4	39

#	Article	IF	Citations
37	Behavioral and metabolic characterization of heterozygous and homozygous POLG mutator mice. Mitochondrion, 2013, 13, 282-291.	3.4	33
38	Frequency of the D620N Mutation in VPS35 in Parkinson Disease. Archives of Neurology, 2012, 69, 1360.	4.5	76
39	Genetic risk factors in Parkinsonâ€™s disease: single gene effects and interactions of genotypes. Journal of Neurology, 2012, 259, 2503-2505.	3.6	7
40	An inverse-Warburg effect and the origin of Alzheimerâ€™s disease. Biogerontology, 2012, 13, 583-594.	3.9	73
41	The utility of laser-generated visual-cueing in Parkinsonian patients with gait freezing. Parkinsonism and Related Disorders, 2012, 18, 401.	2.2	0
42	Singing in groups for Parkinson's disease (SING-PD): A pilot study of group singing therapy for PD-related voice/speech disorders. Parkinsonism and Related Disorders, 2012, 18, 548-552.	2.2	48
43	Metaâ€analysis of Parkinson's Disease: Identification of a novel locus, RIT2. Annals of Neurology, 2012, 71, 370-384.	5.3	264
44	Somatic mitochondrial DNA mutations in early parkinson and incidental lewy body disease. Annals of Neurology, 2012, 71, 850-854.	5.3	103
45	Pgc-1Î± Overexpression Downregulates Pitx3 and Increases Susceptibility to MPTP Toxicity Associated with Decreased Bdnf. PLoS ONE, 2012, 7, e48925.	2.5	63
46	Mitochondria and Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-2.	1.1	3
47	Do Somatic Mitochondrial DNA Mutations Contribute to Parkinson's Disease?. Parkinson's Disease, 2011, 2011, 1-9.	1.1	12
48	The c.â€237_236GA>TT THAP1 sequence variant does not increase risk for primary dystonia. Movement Disorders, 2011, 26, 549-553.	3.9	24
49	Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease. BMC Medical Genetics, 2010, 11, 53.	2.1	26
50	Association of Cumulative Lead Exposure with Parkinsonâ€™s Disease. Environmental Health Perspectives, 2010, 118, 1609-1613.	6.0	137
51	MELAS syndrome, cardiomyopathy, rhabdomyolysis, and autism associated with the A3260G mitochondrial DNA mutation. Biochemical and Biophysical Research Communications, 2010, 402, 443-447.	2.1	28
52	Oral N-Acetyl-Cysteine Attenuates Loss of Dopaminergic Terminals in Î±-Synuclein Overexpressing Mice. PLoS ONE, 2010, 5, e12333.	2.5	97
53	Novel human pathological mutations. Gene symbol: THAP1. Disease: dystonia 6. Human Genetics, 2010, 127, 470.	3.8	1
54	Do mtDNA deletions drive premature aging in mtDNA mutator mice?. Aging Cell, 2009, 8, 502-506.	6.7	40

#	Article	IF	Citations
55	Transcribe to Survive: Transcriptional Control of Antioxidant Defense Programs for Neuroprotection in Parkinsonâ€™s Disease. Antioxidants and Redox Signaling, 2009, 11, 509-528.	5.4	88
56	Noninvasive Brain Stimulation for Parkinsonâ€™s Disease and Dystonia. Neurotherapeutics, 2008, 5, 345-361.	4.4	121
57	Caffeine and Progression of Parkinson Disease. Clinical Neuropharmacology, 2008, 31, 189-196.	0.7	35
58	Mitochondrial Complex I Gene Variant Associated With Early Age at Onset in Spinocerebellar Ataxia Type 2. Archives of Neurology, 2007, 64, 1042.	4.5	30
59	Dystonia. New England Journal of Medicine, 2006, 355, 818-829.	27.0	243
60	Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators. Cell, 2006, 127, 397-408.	28.9	1,948
61	Mitochondrial Cyclic AMP Response Element-binding Protein (CREB) Mediates Mitochondrial Gene Expression and Neuronal Survival. Journal of Biological Chemistry, 2005, 280, 40398-40401.	3.4	187
62	Somatic mitochondrial DNA mutations in single neurons and glia. Neurobiology of Aging, 2005, 26, 1343-1355.	3.1	77
63	Mistaken diagnosis of psychogenic gait disorder in a man with status cataplecticus ("Limp Man) Tj ETQq1 1 0.784314 rgBT /Overlock	3.9	20
64	Attenuation of free radical production and paracrystalline inclusions by creatine supplementation in a patient with a novel cytochromeb mutation. Muscle and Nerve, 2004, 29, 537-547.	2.2	43
65	Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinsonâ€™s disease. Neurobiology of Aging, 2004, 25, 71-81.	3.1	110
66	A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia. Neurogenetics, 2003, 4, 199-205.	1.4	38
67	A Common NURR1 Polymorphism Associated With Parkinson Disease and Diffuse Lewy Body Disease. Archives of Neurology, 2003, 60, 722.	4.5	90
68	High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Human Molecular Genetics, 2002, 11, 133-145.	2.9	318
69	A frameshift mitochondrial complex I gene mutation in a patient with dystonia and cataracts: is the mutation pathogenic?. Journal of Medical Genetics, 2001, 38, 58-61.	3.2	12
70	Plasticity in the Development of Topographic Order in the Mammalian Retinocollicular Projection. Developmental Biology, 1994, 162, 384-393.	2.0	48
71	Responses of retinal axons in vivo and in vitro to position-encoding molecules in the embryonic superior colliculus. Neuron, 1992, 9, 977-989.	8.1	99
72	Influence of position along the medial-lateral axis of the superior colliculus on the topographic targeting and survival of retinal axons. Developmental Brain Research, 1992, 69, 167-172.	1.7	42

#	Article	IF	Citations
73	Relationship of retinotopic ordering of axons in the optic pathway to the formation of visual maps in central targets. Journal of Comparative Neurology, 1991, 307, 393-404.	1.6	67
74	Limited topographic specificity in the targeting and branching of mammalian retinal axons. Developmental Biology, 1990, 137, 125-134.	2.0	96